This sale was conducted under a pre-established trading plan, adopted on March 13, 2024, as part of a Rule 10b5-1 plan, which allows insiders to set up a trading plan for selling stocks they own. Following this transaction, Maroney retains ownership of 1,636,097 shares in the company. With a market capitalization of $2.07 billion, InvestingPro analysis suggests ALHC is currently trading slightly below its Fair Value, while maintaining a “GOOD” overall financial health score. Subscribers to InvestingPro can access detailed insights through the comprehensive Pro Research Report, which provides in-depth analysis of ALHC alongside 1,400+ other US stocks. With a market capitalization of $2.07 billion, InvestingPro analysis suggests ALHC is currently trading slightly below its Fair Value, while maintaining a “GOOD” overall financial health score. Subscribers to InvestingPro can access detailed insights through the comprehensive Pro Research Report, which provides in-depth analysis of ALHC alongside 1,400+ other US stocks. This sale was conducted under a pre-established trading plan, adopted on March 13, 2024, as part of a Rule 10b5-1 plan, which allows insiders to set up a trading plan for selling stocks they own. Following this transaction, Maroney retains ownership of 1,636,097 shares in the company.
In other recent news, Alignment Healthcare has reported robust growth in its third-quarter results for 2024, with a significant 58% increase in health plan membership and a 52% rise in total revenue, reaching $692 million. The company’s adjusted EBITDA turned positive at $6 million, marking the second consecutive quarter of profitability. In light of these developments, TD Cowen, a financial services firm, has upgraded its valuation of Alignment Healthcare, increasing the price target to $13.00 from the previous $10.00, while maintaining a Buy rating on the company’s stock. The company’s management has also expressed confidence in reaching an adjusted EBITDA of over $40 million by 2025, along with a minimum of 20% growth in Medicare Advantage membership. Furthermore, TD Cowen’s new price target reflects a 0.8x 2025 enterprise value/revenue multiple, indicating a positive outlook on Alignment Healthcare’s financial performance and growth potential in upcoming years. These recent developments emphasize the company’s strong market position and its ability to deliver value to shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
